The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback